Naveris, Inc., a private biotechnology company developing blood tests for early cancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D.,
| WALTHAM, Mass., /PRNewswire/ -- Naveris, Inc., a private biotechnology company developing blood tests for early cancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D., scientific advisors and co-chairs of its Scientific Advisory Board, and announces the presentation of clinical trial data at the American Society for Radiation Oncology annual meeting being held October 21 to October 24, 2018, in San Antonio, TX. Dr. Chera’s and Dr. Gupta’s late-breaking abstract (LBA-6) has been selected for presentation in a special late-breaking session by a panel of peer reviewers, and as one of 10 top-rated studies that will be highlighted in the press program for the 2018 ASTRO Annual Meeting. Dr. Chera will deliver a platform presentation entitled “Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal Cancer” at the annual meeting on Tuesday, October 23, 2018. Naveris, Inc., is the sole developer and provider of NavDx, a liquid biopsy blood test that detects Human Papilloma Virus (HPV)-associated head and neck cancers in patients. NavDx has been demonstrated to detect early recurrences in patients before they would be identified in current clinical practice. Dr. Chera’s platform presentation: About Naveris, Inc. Naveris, Inc. (https://www.naveris.com) is a private biotechnology company focused on developing blood tests for early cancer detection. For additional information, email contact@naveris.com. Media contact:
SOURCE Naveris, Inc. |
View original content:
